Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Markets for Prosthetic Vascular Grafts

This article was originally published in Start Up

Executive Summary

Many large and growing diseases, such as diabetes, cause vessel damage calling for replacement vascular grafts. The European market for prosthetic vascular grafts is today a $343 million industry and growing, according to "The European Prosthetic Vascular Grafts Market," a report just issued y Medtech Insight.

You may also be interested in...



In Vascular Disease, a Sustainable Model for Cell Therapy

If there's one word that ought to sum up the goal of cell therapy today, it's sustainability. Certainly that's the hope of using living cells to restore health and function to diseased tissues so that they perform as the body intended them to. But more to the point, in today's tough financing environment for venture-capital-backed start-ups, sustainability is the watchword for companies facing 15- to 20-year development curves. Tissue-engineered three-dimensional organs are complex, decades-long projects. Embryonic stem cells are much simpler in concept but are far from a commercial reality. Between those two extremes of tissue-engineering, however, there exist some well-defined opportunities, notably in the treatment of blood vessel disease. Start-ups Pervasis and Cytograft are gaining clinical validation in those areas.

Cytograft's New Lifeline for Vascular Surgery

The creation of durable vascular grafts has been a tantalizing objective for multitudes of companies and research efforts that have applied all the disciplines of medical science to it: tissue engineering, cell-therapies, biomaterials, drugs, and combinations of all of those technologies, but without much success. The complexities of creating a functional structure with biological properties has foiled many a research effort. But now Cytograft Tissue Engineering has a new take on tissue engineering. Cytograft produces a living conduit with the handling properties of a native vessel, built exclusively from the patient's own cells. Unlike previous approaches, Cytograft's Lifeline vascular graft does not require synthetic materials or exogenous scaffolds.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: safety debate as more lecanemab data reported; amyloid discussions continue at Alzheimer’s meeting; China COVID unrest affect country’s biotech sector; and Merck’s CMO talks about post-Keytruda plans.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT037449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel